CapsoVision (NASDAQ:CV) Now Covered by Analysts at Roth Capital

Stock analysts at Roth Capital assumed coverage on shares of CapsoVision (NASDAQ:CV) in a research note issued to investors on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $9.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 45.63% from the stock’s previous close.

A number of other brokerages have also recently commented on CV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a research report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CapsoVision currently has an average rating of “Hold” and an average price target of $9.50.

CapsoVision Stock Performance

Shares of CV traded up $0.12 during mid-day trading on Friday, reaching $6.18. 6,750 shares of the company were exchanged, compared to its average volume of 246,728. The business has a 50 day simple moving average of $6.59 and a two-hundred day simple moving average of $6.39. The stock has a market capitalization of $309.31 million and a PE ratio of -13.15. CapsoVision has a 52 week low of $3.43 and a 52 week high of $15.37.

CapsoVision (NASDAQ:CV) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%.The firm had revenue of $3.64 million for the quarter.

Insider Transactions at CapsoVision

In other news, major shareholder Eliyahou Et Al Harari acquired 81,300 shares of CapsoVision stock in a transaction on Wednesday, July 8th. The stock was purchased at an average price of $6.09 per share, with a total value of $495,117.00. Following the completion of the purchase, the insider owned 3,282,051 shares of the company’s stock, valued at approximately $19,987,690.59. The trade was a 2.54% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 156,218 shares of company stock valued at $1,007,902 in the last 90 days. 2.30% of the stock is currently owned by corporate insiders.

Institutional Trading of CapsoVision

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in CapsoVision during the second quarter worth $26,000. Deutsche Bank AG bought a new stake in shares of CapsoVision during the fourth quarter worth about $47,000. Wells Fargo & Company MN increased its position in shares of CapsoVision by 66.4% during the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock worth $67,000 after acquiring an additional 2,508 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of CapsoVision in the 3rd quarter worth about $115,000. Finally, Virtu Financial LLC bought a new position in CapsoVision in the 4th quarter valued at about $128,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.